Multidisciplinary support for young cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the impact of a multidisciplinary day hospitalization program on the quality of life of adolescents and young adults who have completed cancer treatment. Participants aged 15 to 25 will be randomly assigned to either receive this specialized support or standard follow-up care. The study will assess changes in health-related quality of life, anxiety, depression, and emotional competence over the first year after treatment completion. The goal is to provide tailored support during a critical transition period for young cancer survivors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be aged between 15 and 25 years at diagnosis. This age range corresponds to the one chosen at the Leon Berard comprehensive cancer care center (CLB) for support in the AYA Department.
2. Be previously treated at the Paediatric Hematology and Oncology Institute (IHOPe) and/or at CLB in AYA Department
3. For a solid tumor or a lymphoma
4. Be in complete oncological response at the end of treatment; have received their end-of-treatment evaluation
5. Have finished their therapy since less than 2 months (therapy is defined by any treatment received, including maintenance)
6. Be capable of understanding, reading and writing French
7. Be affiliated to a health insurance plan
8. Have been informed of the study and have consented to it
9. For minor patients, consent of parents and/or legal tutors must be collected.

Exclusion Criteria:

1. cannot be followed-up throughout the duration of the study (12 months),
2. be deprived of liberty by a court or administrative decision,
3. have not consent to participate or are incapable of objecting in an informed manner.

Where it's running

• Centre Leon Berard
  Lyon, France Recruiting

Study contacts

• Principal investigator: Amandine BERTRAND, MD — Institut d'Hématologie et d'Oncologie Pédiatrique
• Study coordinator: Amandine BERTRAND, MD
• Email: Amandine.BERTRAND@ihope.fr
• Phone: 04787872606

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing CTS3497 for patients with specific cancer types

  This study is testing a new drug called CTS3497 to see if it can help patients with certain hard-to-treat cancers that have not responded to other treatments.

  Recruiting Phase 1/2 CytosinLab Therapeutics Co., Ltd. · Beijing, Beijing Municipality · NCT06971523

• Lutetium Lu 177 Edotreotide dose-finding for children with SSTR-positive tumors

  This test gives Lutetium Lu 177 Edotreotide to children ages 2 to under 18 with somatostatin receptor–positive tumors to find a safe pediatric dose and see how the drug behaves in the body.

  Recruiting at 9 sites Phase 1 ITM Solucin GmbH · Palo Alto, California and 8 other locations · NCT06441331

• Using CAN2109 to treat advanced solid tumors and lymphomas

  This study is testing a new treatment called CAN2109 that is injected directly into tumors to see if it can help people with advanced solid tumors and lymphomas feel better.

  Recruiting Phase 1 Canwell Biotech Limited · Guangzhou, Guangdong · NCT06332430

• A network for collaborative cancer research in Ontario

  This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.

  Recruiting at 2 sites University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT05403177

• Evaluating LB1410 for advanced solid tumors and lymphoma

  This study is testing a new treatment called LB1410 to see if it is safe and effective for people with advanced solid tumors or lymphoma.

  Recruiting Phase 1 L & L Bio Co., Ltd., Ningbo, China · Shanghai, Shanghai Municipality · NCT05357651

• Evaluating NUC-7738 for advanced solid tumors and lymphoma

  This study is testing a new treatment called NUC-7738, alone or with another drug, to see if it helps people with advanced solid tumors and lymphoma, especially those who haven't responded to other therapies.

  Recruiting at 9 sites Phase 1/2 NuCana plc · Cambridge and 8 other locations · NCT03829254

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.